News is a wild mix: a promising new drug collab, but also legal probes and an EU dosing setback. The stock's been choppy, closing at $1.73. The 9-period EMA is dipping below the 21-period—a bearish signal—and the RSI is stuck in the low 40s, showing weak momentum. The volume spike on the drop suggests sellers are in control. Until the legal clouds clear, this feels like a SELL. Too much turbulence. ⚖️ #BiotechRollercoaster

EMA setback has this biotech in the doghouse, but the technicals whisper "oversold bounce." RSI is crawling out of the basement and volume is perking up. It's a speculative punt, but the risk/reward here is spicy. I'm calling a tactical BUY for the brave. #BiotechBet 🧪

Big news week for Protalix! Elfabrio's flying off the shelves, they're debt-free, and just joined the Russell indexes. 📈 The stock's finally waking up, busting through resistance with solid volume. RSI is strong but not screaming overbought yet. This looks like the start of a real move. All signs point to a BUY on this momentum. #Breakout

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.

Protalix BioTherapeutics, Inc. PLX: 2.275 USD

Bullish views

Bearish views